Core Insights - NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, reporting a business update and second quarter 2025 financial results [1][8] Business Highlights and Near-Term Milestones - The strategic acquisition of global rights for SIM0505, targeting CDH6, positions NextCure uniquely in the antibody-drug conjugate (ADC) field, with plans to dose the first patient in the U.S. this quarter [2][6] - NextCure is currently in cohort 4 of the Phase 1 trial for LNCB74 (B7-H4 ADC) and plans to provide updates on both SIM0505 and LNCB74 by Q4 2025, along with proof of concept data in the first half of 2026 [6][7] Financial Results - As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $35.3 million, down from $68.6 million as of December 31, 2024, primarily due to operational funding [5][15] - Research and development expenses for Q2 2025 were $24.1 million, an increase from $12.4 million in Q2 2024, largely due to $17.0 million in up-front license fees [13] - The net loss for Q2 2025 was $26.8 million, compared to a net loss of $15.4 million in Q2 2024, reflecting the impact of the license fee [13][14]

Core Insights - NextCure, Inc. presented new preclinical data showing that NC605, an anti-Siglec-15 antibody, improves bone microarchitecture and reduces fracture incidence in a model of osteogenesis imperfecta (OI) compared to anti-sclerostin treatment [1][4] - OI is characterized by high bone turnover and fragility, with no current cure available; existing treatments increase bone density but compromise bone quality [2] - The study demonstrated that NP159, a surrogate for NC605, significantly enhanced bone mineral density and reduced fracture rates in OI mice [3] Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients who do not respond to existing treatments, utilizing differentiated mechanisms such as antibody-drug conjugates [6] - The company is seeking financial support to advance NC605 towards an Investigational New Drug submission within the next 12 to 18 months [5]